
The U.S. Department of Justice said the Drug Enforcement Administration is now issuing federal registrations to hundreds of state‑licensed medical marijuana dispensaries. The first batch includes over 900 dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.
The registrations come from an Attorney General order issued on April 23 that creates a federal regulatory scheme for certain medical‑marijuana activities while keeping them under the Controlled Substances Act.
To get a registration, a dispensary had to be licensed by its state and then pass a DEA pre‑registration investigation. State licensure alone does not guarantee a federal registration. Once registered, dispensaries must follow federal rules on security, record‑keeping, inventory controls and other safeguards that apply to controlled substances.
Source: U.S. Department of Justice
Registered dispensaries can legally sell medical marijuana that meets the new Schedule III standards. Patients in the covered states may have broader, federally‑backed access to products for chronic pain. For businesses, the registration allows them to operate under federal oversight, which could make banking and insurance easier.
Dispensaries that applied within the initial 60‑day window but are still pending can continue limited transactions with other qualified applicants while their applications are reviewed.
The order does not affect recreational marijuana or any medical‑marijuana activity outside the defined scope. Those activities remain classified as Schedule I drugs, which are illegal under federal law.
The Justice Department will keep prosecuting illegal marijuana trafficking even as it rolls out the new registration process.
If you run a medical‑marijuana dispensary, ensure you have completed the DEA’s pre‑registration investigation and that your state license aligns with federal requirements. Keep detailed records of inventory and security measures to stay compliant.
Patients should verify that their dispensary has received federal registration before purchasing, especially if they need to use banking services that require federal compliance.
Anyone unsure about their status or obligations should consider consulting a lawyer familiar with federal drug regulations.
The registrations give qualifying dispensaries a legal foothold under federal law, which could improve access and banking options for patients.
Dispensaries now must meet strict federal security and record‑keeping standards, adding operational costs and oversight.
The DEA will continue a phased rollout, so more dispensaries and eventually manufacturers and distributors may receive registrations.
Consumers should confirm their dispensary’s federal registration to ensure product legitimacy and smoother banking.
The order does not change the Schedule I status of recreational marijuana, so those activities stay illegal under federal law.
Federal rules apply nationwide, but your options depend on your state and situation. Browse attorneys by practice area, then pick your state.
This article is general information based on U.S. Department of Justice and court or agency records available at publication time. It is not legal advice; laws and deadlines differ by state and by case. Published October 30, 2026.
Source: U.S. Department of Justice
A coalition of 21 attorneys general filed a lawsuit in Oregon federal court to block Treasury rules that would exempt many companies from reporting beneficial ownership, arguing the rules violate the Corporate Transparency Act and…
The Department of Justice and HHS launched a pilot program allowing healthcare companies to self-disclose false claims and resolve past misconduct.
The DOJ's new Fraud Whistleblower Incentive Program will pay $10,000‑$30,000 for tips that lead to criminal charges, focusing on health‑care and federal benefit fraud.
Thousands of consumers who lost money through Walmart wire transfer services are receiving checks totaling more than $9.8 million from the FTC.
The agency now allows Anktiva with BCG for adults whose high‑grade papillary‑only bladder tumors have not responded to BCG, the first such approval.